



NeuraMetrix, Inc. **detects and measures** brain disorders and injuries with **non-invasive** software that measures **sub-clinical** human cognitive and motor function based on **typing cadence**

Mission To provide quantitative measurement tools which are the standard for early detection, measurement, and monitoring of brain health

Goal To be the leading independent brain health monitoring company by building the world's most innovative and effective brain health monitoring platform

Overview Disruptive technology to detect/monitor progression of brain disorders

- Initial study with MJFF Fox Trial Finders completed on Parkinson's Disease
- Vast implications for patients, neurologists and big pharma/biotech

Remote, real-time, continuous monitoring

- Improved disease management by neurologists
- Objective data regarding treatment changes
- Seamlessly connects neurologists and patients via "dashboards"

Online, highly-scalable, cost-effective non-invasive solution

- Patients measured during "natural typing behavior"
- Independent of language, culture or education
- Does not require tests, sensors, gross motor skills or physician interaction
- Fully integrated online technology platform – software solution
- Results are automatically measured, analyzed and reported

Early detection/measurement enable development of new therapies

Scientific Advisory Board Robert W. Mahley, MD, PhD, Chairman (Gladstone Institutes)
Carolee Barlow, MD, PhD (Parkinson's Institute and Clinical Center)
Wolfgang H. Oertel, MD (Philipps-Universität Marburg)
Bruce L. Miller, MD (UCSF)

Active Research	Disease/Disorder	Research Affiliates
	Parkinson's Disease	Karolinska Institutet, Stockholm (Sweden)
	Alzheimer's	Parkinson's Institute and Clinical Center (US)
	ADHD	Philipps-Universität Marburg (Germany)
	Depression	Sogn og Fjordane University College (Norway)
	Huntington's Disease	Stanford University (US)
	REM Sleep Behavior Disorder	University of St Andrews (Scotland)
	Wolfram Syndrome	University of Toronto (Canada)
		University of Ulm (Germany)
		University of Iowa (US)
		Washington University, St Louis (US)

Applications Patient monitoring/med management
Drug development/clinical trials
Early detection/diagnostics

Contact Jan Samzelius, CEO (jan.samzelius@neurametrix.com, 415-420-6636)
Bill Wisialowski, COO (wiz@neurametrix.com, 650-773-1441)

